166 related articles for article (PubMed ID: 21611102)
1. Cetuximab concomitant with second-line radiation therapy in patients with locally advanced recurrent squamous cell head and neck cancer.
Akmansu M; Buyukberber S; Iren S; Demirci U; Kanyilmaz G; Coskun U; Bora H
Case Rep Oncol; 2010 Sep; 3(3):480-8. PubMed ID: 21611102
[TBL] [Abstract][Full Text] [Related]
2. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
4. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.
Rühle A; Sprave T; Kalckreuth T; Stoian R; Haehl E; Zamboglou C; Laszig R; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Apr; 15(1):81. PubMed ID: 32299456
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F
Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383
[TBL] [Abstract][Full Text] [Related]
6. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
7. Concurrent Radiotherapy With Cetuximab or Platinum-based Chemotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Lu SM; Lien WW
Am J Clin Oncol; 2018 Jan; 41(1):95-99. PubMed ID: 26353121
[TBL] [Abstract][Full Text] [Related]
8. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
Bernier J; Russi EG; Homey B; Merlano MC; Mesía R; Peyrade F; Budach W
Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity.
Acevedo-Henao CM; Valette G; Miglierini P; Lefur E; Pradier O
Cancer Radiother; 2012 Oct; 16(7):601-3. PubMed ID: 23089070
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.
Tao Y; Faivre L; Laprie A; Boisselier P; Ferron C; Jung GM; Racadot S; Gery B; Even C; Breuskin I; Bourhis J; Janot F
Radiother Oncol; 2018 Sep; 128(3):467-471. PubMed ID: 29784451
[TBL] [Abstract][Full Text] [Related]
11. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis.
Roesch J; Oertel M; Wegen S; Trommer M; Schleifenbaum J; Hering D; Mäurer M; Knippen S; Dobiasch S; Waltenberger M; von der Grün J; Medenwald D; Süß C; Hoeck M; Käsmann L; Fleischmann DF; Rühle A; Nicolay NH; Fabian A; Löser A; Heß S; Tamaskovics B; Vinsensia M; Hecht M;
Radiother Oncol; 2023 Apr; 181():109380. PubMed ID: 36273736
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
14. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.
Matuschek C; Bölke E; Belka C; Ganswindt U; Henke M; Stegmaier P; Bamberg M; Welz S; Debus J; Gioules A; Voigt A; Volk G; Ohmann C; Wiegel T; Budach V; Stuschke M; Schipper J; Gerber PA; Budach W
Strahlenther Onkol; 2013 Aug; 189(8):625-31. PubMed ID: 23824104
[TBL] [Abstract][Full Text] [Related]
16. [Postoperative radiotherapy with cetuximab for head and neck squamous cell carcinoma patients at high risk of recurrence not eligible for cisplatin: A single-center experience and literature review].
Marques O; Brenet E; Gaultier V; Marchand-Crety C
Cancer Radiother; 2023 Feb; 27(1):17-22. PubMed ID: 35853823
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience.
Jensen AD; Bergmann ZP; Garcia-Huttenlocher H; Freier K; Debus J; Münter MW
Head Neck Oncol; 2010 Nov; 2():34. PubMed ID: 21110844
[TBL] [Abstract][Full Text] [Related]
18. Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer.
Frank DK; Hu KS; Culliney BE; Persky MS; Nussbaum M; Schantz SP; Malamud SC; Holliday RA; Khorsandi AS; Sessions RB; Harrison LB
Laryngoscope; 2005 Jun; 115(6):1015-20. PubMed ID: 15933512
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
Sun L; Candelieri-Surette D; Anglin-Foote T; Lynch JA; Maxwell KN; D'Avella C; Singh A; Aakhus E; Cohen RB; Brody RM
JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1022-1028. PubMed ID: 36136306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
